**4. Conclusions**

Patients with BMs, especially those who have them in the spine, have a worse prognosis than those with lung metastasis in multiple cancer subtypes. However, the prognosis of patients with BM from DTC is still favorable compared to that of patients with other cancers. Patients with osteolytic BMs from thyroid carcinoma often have a significantly reduced PS. The PS affects mortality directly and indirectly by hampering the application of systemic therapies using RAI and/or KIs, which are the mainstay of treatment for patients with metastatic DTC. Therefore, long-term local control of BMs from DTC is desirable, especially in patients with single or oligometastases. Along with systemic therapies, local therapies, including metastasectomy and SRS, can be valuable as treatment options, and even as curative measures of BM in selected patients. Recent advancements in local therapies have the potential to provide not only long-term local tumor control but also a better prognosis.

**Author Contributions:** Writing the original draft, S.K.; writing the review and editing, S.D., K.S., N.Y., T.S. and H.T. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.
